Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children
- PMID: 15665711
- DOI: 10.1097/01.inf.0000148928.10057.86
Comparative trial of the safety and immunogenicity of quadrivalent (A, C, Y, W-135) meningococcal polysaccharide-diphtheria conjugate vaccine versus quadrivalent polysaccharide vaccine in two- to ten-year-old children
Abstract
Background: A quadrivalent meningococcal diphtheria conjugate vaccine (MCV-4) has been developed to provide T-cell dependent immune responses against 4 major disease-causing serogroups (A, C, Y, W-135).
Methods: In a comparative, randomized, modified double blind, controlled study in healthy 2- to 10-year-old U.S. children, safety and immunogenicity profiles of MCV-4 (n = 696) were compared with those of a licensed quadrivalent polysaccharide vaccine, Menomune A/C/Y/W-135 (PSV-4, n = 702). Vaccine-related adverse reactions were assessed for 28-day and 6-month follow-up periods. Serum bactericidal activity (SBA) was assayed in prevaccination, day 28 and 6-month postvaccination sera samples.
Results: Both vaccines were well-tolerated, with no vaccine-related serious adverse events and similar rates of mostly mild local and systemic reactions. Functional antibody (SBA) seroconversion percentages were significantly higher for all 4 serogroups in the MCV-4 group. The SBA geometric mean titers against serogroups A, C, Y and W-135 with MCV-4 were 1700, 354, 637 and 750, respectively, compared with PSV-4 (893, 231, 408 and 426) 28 days postvaccination (P < 0.001 for all comparisons). This significant difference persisted through 6 months.
Conclusions: In 2- to 10-year-old children MCV-4 had a safety profile similar to that of PSV-4 and elicited significantly higher and more persistent serum bactericidal antibody responses against meningococcal serogroups A, C, Y and W-135 than did the licensed polysaccharide vaccine.
Similar articles
-
Safety, immunogenicity, and immune memory of a novel meningococcal (groups A, C, Y, and W-135) polysaccharide diphtheria toxoid conjugate vaccine (MCV-4) in healthy adolescents.Arch Pediatr Adolesc Med. 2005 Oct;159(10):907-13. doi: 10.1001/archpedi.159.10.907. Arch Pediatr Adolesc Med. 2005. PMID: 16203934 Clinical Trial.
-
Dosage escalation, safety and immunogenicity study of four dosages of a tetravalent meninogococcal polysaccharide diphtheria toxoid conjugate vaccine in infants.Pediatr Infect Dis J. 2004 May;23(5):429-35. doi: 10.1097/01.inf.0000126297.28952.f8. Pediatr Infect Dis J. 2004. PMID: 15131466 Clinical Trial.
-
Safety and immunogenicity of a meningococcal (Groups A, C, Y, W-135) polysaccharide diphtheria toxoid conjugate vaccine in healthy children aged 2 to 10 years in Chile.Hum Vaccin. 2005 Nov-Dec;1(6):228-31. doi: 10.4161/hv.1.6.2301. Epub 2005 Nov 7. Hum Vaccin. 2005. PMID: 17012878 Clinical Trial.
-
Meningococcal quadrivalent (serogroups A, C, W135 and Y) tetanus toxoid conjugate vaccine (Nimenrix™).Drugs. 2012 Dec 24;72(18):2407-30. doi: 10.2165/11209580-000000000-00000. Drugs. 2012. PMID: 23231026 Review.
-
Prospects for vaccine prevention of meningococcal infection.Clin Microbiol Rev. 2006 Jan;19(1):142-64. doi: 10.1128/CMR.19.1.142-164.2006. Clin Microbiol Rev. 2006. PMID: 16418528 Free PMC article. Review.
Cited by
-
Role of factor H binding protein in Neisseria meningitidis virulence and its potential as a vaccine candidate to broadly protect against meningococcal disease.Microbiol Mol Biol Rev. 2013 Jun;77(2):234-52. doi: 10.1128/MMBR.00056-12. Microbiol Mol Biol Rev. 2013. PMID: 23699256 Free PMC article. Review.
-
Advice for Consideration of Quadrivalent (A, C, Y, W135) Meningococcal Conjugate Vaccine, for use by Provinces and Territories.Can Commun Dis Rep. 2010 Jan 26;36(Suppl 2):1-35. doi: 10.14745/ccdr.v36i00as2. eCollection 2010 Jan 26. Can Commun Dis Rep. 2010. PMID: 31680692 Free PMC article. No abstract available.
-
Protein carriers of conjugate vaccines: characteristics, development, and clinical trials.Hum Vaccin Immunother. 2013 Dec;9(12):2505-23. doi: 10.4161/hv.26109. Epub 2013 Aug 16. Hum Vaccin Immunother. 2013. PMID: 23955057 Free PMC article. Review.
-
Novel polysaccharide-protein conjugates provide an immunogenic 13-valent pneumococcal conjugate vaccine for S. pneumoniae.Synth Syst Biotechnol. 2017 Jan 20;2(1):49-58. doi: 10.1016/j.synbio.2016.12.002. eCollection 2017 Mar. Synth Syst Biotechnol. 2017. PMID: 29062961 Free PMC article.
-
Bacterial meningitis vaccines: not just for kids.Curr Infect Dis Rep. 2009 Jul;11(4):302-8. doi: 10.1007/s11908-009-0045-z. Curr Infect Dis Rep. 2009. PMID: 19545500
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical